Neurological disorders such as Alzheimer's and Parkinson's disease present major challenges due to their progressive nature and the limited efficacy of current treatments. This review paper presents a detailed examination of current pharmacological strategies and emerging therapies for AD and PD. For AD, the focus has been on cholinesterase inhibitors (ChEIs) and NMDA receptor antagonists, which aim to mitigate cognitive decline and slow disease progression. In PD, the standard treatments involve dopaminergic agents, including levodopa and dopamine agonists, which target motor symptoms. Recent advancements include the exploration of innovative therapies such as anti-tau agents for AD, which target tau protein aggregates, and gene therapy for PD, which seeks to address dopamine deficits at a genetic level. Additionally, non-pharmacological treatments, such as cognitive training, physical exercise, and psychosocial interventions, play a crucial role in enhancing cognitive and functional outcomes alongside pharmacological therapies. Despite these advancements, significant challenges remain, particularly in developing disease-modifying treatments and optimizing therapeutic efficacy. This review highlights the need for continued research to better understand and improve treatment strategies, integrating both pharmacological and non-pharmacological approaches. By adopting a comprehensive and multi-faceted treatment strategy, the aim is to provide enhanced care and improved quality of life for individuals suffering from AD and PD.